AKT1 and metabolic syndrome: In addition, EETs decrease MSC-derived adipocyte stem cell differentiation by the upregulation of HO-1-adiponectin-AKT signalling, suggesting that EET agonist may have potential therapeutic role in the treatment of dyslipidemia, diabetes, and the metabolic syndrome [108].